Search Results - "Kullab, S."

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact by Nabholtz, J.M., Abrial, C., Mouret-Reynier, M.A., Dauplat, M.M., Weber, B., Gligorov, J., Forest, A.M., Tredan, O., Vanlemmens, L., Petit, T., Guiu, S., Van Praagh, I., Jouannaud, C., Dubray-Longeras, P., Tubiana-Mathieu, N., Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Radosevic-Robin, N., Kwiatkowski, F., Desrichard, A., Cayre, A., Uhrhammer, N., Chalabi, N., Chollet, P., Penault-Llorca, F.

“…Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors for some of which the epithelial growth factor receptor (EGFR) pathway may play an…”
Get full text

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial by Alsaleh, K., Al Zahwahry, H., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel-Razeq, H., Larbaoui, B., Kandil, A., Abulkhair, O., Al Foheidi, M., Ghosn, M., Rasool, H., Boussen, H., Mezlini, A., Haddaoui, A., Ayari, J., Al Ghamdi, M., Errihani, H., Abdel-Aziz, N., Arafah, M., Dabouz, F., Bahadoor, M., Kullab, S., Nabholtz, J. M.

“…Background The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side…”
Get full text

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer by Nabholtz, J.M., Chalabi, N., Radosevic‐Robin, N., Dauplat, M.M., Mouret‐Reynier, M.A., Van Praagh, I., Servent, V., Jacquin, JP, Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Kwiatkowski, F., Cayre, A., Abrial, C., Durando, X., Bignon, Y.J., Chollet, P., Penault‐Llorca, F.

“…Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in…”
Get full text

A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study) by Nabholtz, J.-M., Al Saleh, K., Bounedjar, A., Abdel-Razeq, H., Errihani, H., Saadeddin, A., Al Foheidi, M., Ghosn, M., El Zawahry, H., Kandil, A., Abdel-Aziz, N., Dabouz, F., Kullab, S.

Get full text

Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: A prospective pilot study by Nabholtz, J-M A, Alsaleh, K.A., Kullab, S., Abdel-Aziz, N., Abdelwarith, A., Diab, A Al, Hilal, M.A., Dabouz, F., Bajic, V., Incitti, R., Bahadoor, M.R.K., Azeer, A.M.

Get full text

1422P - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: A prospective pilot study by Nabholtz, J-M A, Alsaleh, K.A., Kullab, S., Abdel-Aziz, N., Abdelwarith, A., Diab, A Al, Hilal, M.A., Dabouz, F., Bajic, V., Incitti, R., Bahadoor, M.R.K., Azeer, A.M.

“…BC screening by mammography is associated with a significant reduction in mortality (19 % overall reduction of the relative risk), however with significant…”
Get full text

1422PMolecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: A prospective pilot study by Nabholtz, J-M A, Alsaleh, K A, Kullab, S, Abdel-Aziz, N, Abdelwarith, A, Diab, A Al, Hilal, M A, Dabouz, F, Bajic, V, Incitti, R, Bahadoor, M R K, Azeer, A M

“…Abstract Background BC screening by mammography is associated with a significant reduction in mortality (19 % overall reduction of the relative risk), however…”
Get full text

232TiPA multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study) by Nabholtz, J-M, Al Saleh, K, Bounedjar, A, Abdel-Razeq, H, Errihani, H, Saadeddin, A, Al Foheidi, M, Ghosn, M, El Zawahry, H, Kandil, A, Abdel-Aziz, N, Dabouz, F, Kullab, S

Get full text

198PA multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial) by Nabholtz, J-MA, Alsaleh, K A, Bounedjar, A, Oukkal, M, El-Zawahry, H M, Bouzid, K, Razek, H Abdel, Mahfouf, H, Bensalem, A, Saadeddin, A, Filali, T, Larbaoui, B, Abulkhair, O, Al-Foheidi, M, Boussen, H, ayari, J, Ghosn, M, Abdel-Aziz, N, Dabouz, F, Kullab, S

“…Abstract Background NA chemotherapy (CT) +/- anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC…”
Get full text

A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial) by Nabholtz, J-MA, Alsaleh, K.A., Bounedjar, A., Oukkal, M., El-Zawahry, H.M., Bouzid, K., Razek, H Abdel, Mahfouf, H., Bensalem, A., Saadeddin, A., Filali, T., Larbaoui, B., Abulkhair, O., Al-Foheidi, M., Boussen, H., ayari, J., Ghosn, M., Abdel-Aziz, N., Dabouz, F., Kullab, S.

Get full text

198P - A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial) by Nabholtz, J-MA, Alsaleh, K.A., Bounedjar, A., Oukkal, M., El-Zawahry, H.M., Bouzid, K., Razek, H Abdel, Mahfouf, H., Bensalem, A., Saadeddin, A., Filali, T., Larbaoui, B., Abulkhair, O., Al-Foheidi, M., Boussen, H., ayari, J., Ghosn, M., Abdel-Aziz, N., Dabouz, F., Kullab, S.

“…NA chemotherapy (CT) +/- anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC. However, pathologic…”
Get full text

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer: Phase II Study of Cetuximab Combined with Docetaxel for TNBC by Nabholtz, J.M., Chalabi, N., Radosevic-Robin, N., Dauplat, M.M., Mouret-Reynier, M.A., Van Praagh, I., Servent, V., Jacquin, JP, Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Kwiatkowski, F., Cayre, A., Abrial, C., Durando, X., Bignon, Y.J., Chollet, P., Penault-Llorca, F.

Get full text

Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies by Jadallah, Khaled A, Kullab, Susan M, Sanders, David S

“…Irritable bowel syndrome(IBS) is a highly prevalent medical condition that adversely affects patient quality of life and constitutes a significant economic…”
Get full text